.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Merck
McKesson
Queensland Health
Moodys
Daiichi Sankyo
Colorcon
Medtronic
Deloitte
AstraZeneca

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,508,020

« Back to Dashboard

Claims for Patent: 5,508,020

Title: Technetium-99M labeled peptides for imaging
Abstract:This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to peptides, methods and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body labeled with technetium-99m (Tc-99m) via Tc-99m binding moieties. In particular, the peptide reagents of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the specific-binding peptides, and the Tc-99m binding moieties are covalently linked to a plurality of the specific-binding peptides, the polyvalent linker moiety, or to both the specific-binding peptides and the polyvalent linker moiety.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatech, Inc. (Londonderry, NH)
Application Number:07/893,981
Patent Claims: 1. A composition of matter comprising a reagent for preparing a scintigraphic imaging agent for imaging sites within a mammalian body comprising a multiplicity of specific-binding peptides, each specific binding peptide having an amino acid sequence of 3 to 100 amino acids wherein the specific binding peptide specifically binds to a site in a mammalian body, covalently linked to a polyvalent linking moiety, and a technetium-99m binding moiety covalently linked to a plurality of the specific-binding peptides, the polyvalent linker moiety, or both, wherein the reagent is selected from the group consisting of reagents having the formula: ##STR8##

2. A composition of matter having the formula: ##STR9##

3. A composition of matter having the formula: ##STR10##
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Farmers Insurance
Baxter
Chubb
Harvard Business School
Fish and Richardson
Johnson and Johnson
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot